Turnstone Biologics announced that Sammy Farah, Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference.
About Turnstone Biologics
Turnstone Biologics is a clinical-stage, immuno-oncology company developing the next-generation of oncolytic viral immunotherapies for patients with a broad range of solid tumors. The company’s Maraba (MG1) oncolytic virus platform is the first to combine the tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, with the goal of preventing recurrence and delivering a cure. Turnstone is advancing a robust pipeline of early-stage investigational therapies, including MG1-MAGEA3, targeting MAGE-A3 positive solid tumors such as non-small cell lung cancer (NSCLC), which is currently in Phase I/II clinical development as a monotherapy and in combination with a checkpoint inhibitor. Turnstone’s MG1-HPV therapy, targeting HPV positive cancers such as cervical and oropharyngeal cancer, is also entering clinical development after recently receiving U.S. FDA clearance of its IND. Turnstone’s lead investors include Versant Ventures, OrbiMed, F-Prime Capital Partners and FACIT. For more information, please visit http://turnstonebio.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180601005506/en/
Source: Turnstone Biologics
